NPS Melanoma (US)

NPS Melanoma (US)

Code: FW-21072016-44 | Published: Jun-2016 | Pages: 0 | FirstWord
Price :
$2,495.00
USD

* Required Fields

$2,495.00

Details

One brand leads the pack in the US – but who is coming a close second?

When it comes to melanoma treatment options, just how loyal are US oncologists to particular brands? The majority claim to be satisfied with the choices available – however, they are also happy to recommend more than one option. Why?

FirstView’s NPS+ Melanoma report assesses brand loyalty for 7 melanoma treatments. See exactly how your brand is performing and get the insight you need to build a targeted brand strategy and improve your market share.

Get Answers to Key Questions About Melanoma Treatments

Opdivo (nivolumab): What are the vast majority of Opdivo Detractors recommending instead? Could they be persuaded to switch?
Keytruda (pembrolizumab): Which important brand message is not getting through to US oncologists, yet is top of the list amongst their EU counterparts?
Yervoy (ipilimumab): Market share amongst Promoters looks healthy but what does the Yervoy loyalty score reveal about the likelihood of switching?
Zelboraf (vemurafenib): Promoters of Zelboraf strongly favour two other brands – which ones?
Mekinist (trametinib): Do US oncologists view Mekinist and Tafinlar as interchangeable?
Tafinlar (dabrafenib): What does Tafinlar’s brand DNA show about how oncologists view it within the treatment paradigm?
Proleukin (aldesleukin): Which top three brand messages are strongest amongst Promoters? Could these be the key to taking on the two competitor brands leading the field?

Top Takeaways

One brand is healthiest by far: Although all but one of the brands surveyed showed a positive NPS, the leader showed a 31% improvement on second place in the US and a 41% improvement in Europe.
Loyalty is relatively low: 3-4 other choices are actively considered for all brands except one – find out which one.
One brand has a huge opportunity to gain market share: If its Detractors can be converted into Promoters, this brand stands to gain significantly more than any other surveyed.
One key message dominates: Of all the drugs surveyed, one brand message consistently ranked in the top three. Find out which one.

Explore Important Brand Loyalty Issues

NPS+ Melanoma (US) explores key issues affecting brand loyalty for melanoma drug manufacturers. You’ll learn:

How satisfied the melanoma market is.
How loyal doctors are to your brand.
How many other brands your Promoters recommend.
Which other brands your Promoters and Detractors recommend.
How much market share your brand has among Promoters and Detractors.
How much market share you stand to gain by converting Detractors into Promoters.
Which messages Promoters, Passives and Detractors associate with your brand.
Your brand DNA: what doctors really think of your brand—in their own words.

A Report Based on Expert Knowledge

We surveyed 100 US Medical Oncologists chosen from the largest community of validated physicians in the world. The same community that pharma market researchers trust for reliable, fast intelligence.

We conducted the survey between May 12th and 17th, 2016.

What is Net Promoter® Score?
NPS is a customer loyalty metric developed by (and a registered trademark of) Fred Reichheld, Bain & Company, and Satmetrix. It was introduced by Reichheld in his 2003 Harvard Business Review article One Number You Need to Grow.

How does NPS work?
NPS measures overall brand satisfaction and loyalty by asking one simple question:

""How likely are you to recommend this brand to a colleague?""

Responses - given on a scale of 0 (not at all likely) to 10 (extremely likely)—are used to classify respondents into 3 categories:

Detractors are those who answer 0 – 6.
Passives are those who answer 7 – 8.
Promoters are those who answer 9 - 10.

How is NPS calculated?
The percentage of detractors - the percentage of promoters = NPS.
For example, 25% Promoters, 55% Passives and 20% Detractors give you an NPS of +5.
NPS can range from -100 (everybody is a Detractor) to +100 (everybody is a Promoter). The higher the score the healthier the brand.

What is FirstView NPS+?

NPS+ turns your Net Promoter Score into actionable information by answering key questions about brand loyalty.

Each NPS+ report examines doctors’ relationships with the brands used to treat a major disease area—measuring brand loyalty and showing you how it affects your market share. NPS+ also examines “brand DNA”, revealing in doctors’ own words what brands mean to them.

Instead of one simple metric, NPS+ gives you a detailed picture of brand health that highlights areas for improvement, and helps you see exactly what steps you need to take next.

Money Back Guarantee!
At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll refund your money. Guaranteed.

Table of Contents


1.Chart 1: Net Promoter Score?
2.Chart 2: How loyal are doctors to my brand?
3.Chart 3: How satisfied is the market?
4.Chart 4: How many other brands are promoted by my Promoters?
5.Chart 5: Which other brand is most promoted by my Promoters?
6.Chart 6: Which other brands are promoted by my Detractors?
7.Chart 7: What is my brand's market share among Promoters and Detractors?
8.Chart 8: What brand messages are associated with Promoters, Passives and Detractors (by
brand)?
9.Chart 9: What does my brand represent to Promoters and Detractors (by brand)?
10.Appendix

Report Format

Following are different modes of Licenses.

a. Single User License:
This license allows only one person to use the report. This person can use the report on any computer and may take print outs of the report but must take care of not sharing the report (or any information contained therein) with any other individual or people. Unless you purchase a Site License or a Global Site License, a Single User License must be purchased for every single person that wishes to use the report within the same enterprise.

b. Single Site License:
This license allows unlimited users to use the report within one company location, e.g. a regional office. These users can use the report on any computer and may take print outs of the report but must take care of not sharing the report (or any information contained therein) with any other individual or people.

c. Global Site License:
A Global Site License (or Enterprise wide Site License or Global License) is a license granted to original purchaser, who can share a report with other employees and authorized Users of the same organization.

Quick Help

1. How do you deliver the reports?
The delivery of reports is depends on format & mode of license of report(s). Following are different kinds of formats of report(s) and their delivery options :

a. Electronic Format – Through email from Publisher
Report will be sent to your username email address in PDF, Excel, PowerPoint or any other electronic / softcopy format by publisher.
Delivery Time: 12 to 48 hours [depending on time difference or occurrences of national holidays]

b. Hard Copy or Printed Format or CD-Rom – Through Mail or Courier from Publisher
Report will be sent through mail / courier delivery to your shipping address by publisher.
Delivery Time: Less than, few weeks [depending on time difference or occurrences of national holidays]


2. How can I make payment for publications I purchase?
You could be able to make the payment, in following ways:

a. Online Secure Payment through Credit Card Payment : We accept Visa, Master, AMEX Cards & CCAvenue
b. Transfer of fund to our bank account via Bank transfer or Wire transfer
c. Payment via DD or Cheque
d. Paypal


3. Is it safe to use my credit card on MarketinfoResearch?
Your personal information and online tranaction on Marketinfo Research is secure, private, and tamper-proof. All credit card payments are processed through secure and trusted payment gateways.

If you have a more question about our publications please see our FAQs section or contact us now at cs@marketinforesearch.com.

Browse similar reports by category:
Pharmaceuticals & Healthcare
FirstWord

Our Clients